Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 7;13(4):314. doi: 10.1038/s41419-022-04736-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — A Representative images of tumor morphology. B Data analysis of tumor volume. C Representative IHC staining of Ki-67 expression in tumors. D Quantitative expression analysis of lncRNA-Gm31932 in tumors by RT-qPCR. E Quantitative expression analysis of miR-344d-3-5p in tumors by RT-qPCR. F Changes in the melanin content of tumors. G Changes in the tyrosinase activity of tumors. H Quantitative expression analyses of Prc1 and Nuf2 in tumors by RT-qPCR. I The protein levels of PRC1 and NUF2 in tumors were determined by western blot. J Quantitative analysis of the protein levels of PRC1 and NUF2 in tumors. K Western blotting for CDK2, CDC2, and Cyclin B1 in tumors. L Quantitative analysis of protein levels of CDK2, CDC, and Cyclin B1 in tumors. M Western blotting of P21 and P27 in tumors. N Quantitative analysis of the protein level of P21 and P27 in tumors. O Western blotting for WNT1 and β-catenin in tumors. P Quantitative analysis of the protein level of WNT1 and β-catenin in tumors. n = 8. Data are presented as the mean ± SD. *P < 0.05, **P < 0.01 compared with the corresponding control group by Student’s t-test.